Floatz logo

Visugromab

Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

CatalYm GmbHmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

180 Active assets in the Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB

View all 50 →

Same molecule, other indications

Visugromab is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Adult Solid TumorDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →